Previous 10 | Next 10 |
EVANSTON, Ill., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live w...
EVANSTON, Ill., July 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Joseph Moskal, Ph.D., the company’s chief scient...
Aptinyx (NASDAQ: APTX ) has entered into a sales agreement with Cowen and Company, LLC, to offer and sell common shares up to $50M. More news on: Aptinyx Inc., Healthcare stocks news, Read more ...
"When the competent men of the system are compelled to quit, the system will soon quit itself." - Amit Kalantri Today, we look at a small Busted IPO in the biotech sector. The stock has lost over 80% of its value since coming public in 2018. However, some upcoming data readouts could alter...
EVANSTON, Ill., June 26, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the presentation of preclinical data on its novel NMDA recep...
Guardion Health Sciences (NASDAQ: GHSI ) +35% on receiving a patent from the European Union for its proprietary medical device, the MapcatSF. More news on: Guardion Health Sciences, Inc., DiaMedica Therapeutics Inc., Melinta Therapeutics, Inc., Stocks on the move, Read more .....
EVANSTON, Ill., June 18, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Ashish Khanna, chief financial officer and chief b...
Provention Bio (NASDAQ: PRVB ) +170% on potential of teplizumab to delay diabetes. More news on: Provention Bio, Inc., Tableau Software, Inc., Tilray, Inc., Stocks on the move, Read more ...
Thinly traded micro cap Aptinyx (NASDAQ: APTX ) is up 14% premarket on average volume in response to positive Phase 2 data on NMDA modulator NYX-2925 in 23 patients with fibromyalgia , a disorder characterized by widespread musculoskeletal pain. More news on: Aptinyx Inc., H...
NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with patient-reported pain improvements NYX-2925 was well tolerated with no serious adverse events ...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...